Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Pruritus Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Pruritus Overview | 11 | 1 |
| Pipeline Products for Pruritus Comparative Analysis | 12 | 1 |
| Pruritus Therapeutics under Development by Companies | 13 | 2 |
| Pruritus Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
| Pruritus Pipeline Products Glance | 16 | 3 |
| Late Stage Products | 16 | 1 |
| Clinical Stage Products | 17 | 1 |
| Early Stage Products | 18 | 1 |
| Pruritus Products under Development by Companies | 19 | 2 |
| Pruritus Products under Investigation by Universities/Institutes | 21 | 1 |
| Pruritus Companies Involved in Therapeutics Development | 22 | 25 |
| Albireo AB | 22 | 1 |
| Alveonix AG | 23 | 1 |
| Amorepacific Corporation | 24 | 1 |
| Asana BioSciences, LLC | 25 | 1 |
| Cara Therapeutics, Inc. | 26 | 1 |
| Chugai Pharmaceutical Co., Ltd. | 27 | 1 |
| Creabilis SA | 28 | 1 |
| ELORAC, Inc. | 29 | 1 |
| Faes Farma, S.A. | 30 | 1 |
| GlaxoSmithKline Plc | 31 | 1 |
| Hydra Biosciences, Inc. | 32 | 1 |
| LEO Pharma A/S | 33 | 1 |
| Merck &Co., Inc. | 34 | 1 |
| NeRRe Therapeutics Ltd | 35 | 1 |
| Nippon Shinyaku Co., Ltd. | 36 | 1 |
| Patara Pharma, Inc. | 37 | 1 |
| Phosphagenics Limited | 38 | 1 |
| RDD Pharma Ltd. | 39 | 1 |
| Sanwa Kagaku Kenkyusho Co., Ltd. | 40 | 1 |
| Shionogi &Co., Ltd. | 41 | 1 |
| Sumitomo Dainippon Pharma Co., Ltd. | 42 | 1 |
| Teikoku Pharma USA, Inc. | 43 | 1 |
| Tioga Pharmaceuticals, Inc. | 44 | 1 |
| Trevi Therapeutics, Inc. | 45 | 1 |
| Vanda Pharmaceuticals Inc. | 46 | 1 |
| Pruritus Therapeutics Assessment | 47 | 10 |
| Assessment by Monotherapy Products | 47 | 1 |
| Assessment by Target | 48 | 2 |
| Assessment by Mechanism of Action | 50 | 3 |
| Assessment by Route of Administration | 53 | 2 |
| Assessment by Molecule Type | 55 | 2 |
| Drug Profiles | 57 | 50 |
| A-4250 Drug Profile | 57 | 2 |
| aprepitant Drug Profile | 59 | 1 |
| asimadoline Drug Profile | 60 | 2 |
| ASN-008 Drug Profile | 62 | 1 |
| Ax-10 Drug Profile | 63 | 1 |
| Ax-8 Drug Profile | 64 | 1 |
| bilastine Drug Profile | 65 | 2 |
| cromolyn sodium Drug Profile | 67 | 1 |
| CT-327 Drug Profile | 68 | 3 |
| CT-340 Drug Profile | 71 | 1 |
| desloratadine Drug Profile | 72 | 2 |
| difelikefalin Drug Profile | 74 | 8 |
| GSK-2330672 Drug Profile | 82 | 1 |
| lidocaine hydrochloride Drug Profile | 83 | 1 |
| nalbuphine hydrochloride ER Drug Profile | 84 | 3 |
| naloxone hydrochloride Drug Profile | 87 | 1 |
| nemolizumab Drug Profile | 88 | 1 |
| NS-141 Drug Profile | 89 | 1 |
| orvepitant maleate Drug Profile | 90 | 2 |
| PAC-14028 Drug Profile | 92 | 2 |
| Peptides to Target TRPV1 for Pain and Itch Drug Profile | 94 | 1 |
| RDD-1609 Drug Profile | 95 | 1 |
| serlopitant Drug Profile | 96 | 2 |
| SK-1405 Drug Profile | 98 | 1 |
| Small Molecule to Agonize CB2 for Pruritus Drug Profile | 99 | 1 |
| Small Molecule to Inhibit Substance P for Pruritus Drug Profile | 100 | 1 |
| Small Molecules to Antagonize Mas-Related G-Protein Coupled Receptor for Pruritus Drug Profile | 101 | 1 |
| Small Molecules to Antagonize TRPV3 for Pruritus and Psoriasis Drug Profile | 102 | 1 |
| Small Molecules to Block NaV1.7 Channel for Pain, Ocular Pain and Pruritus Drug Profile | 103 | 1 |
| TPU-010 Drug Profile | 104 | 1 |
| tradipitant Drug Profile | 105 | 2 |
| Pruritus Dormant Projects | 107 | 2 |
| Pruritus Discontinued Products | 109 | 1 |
| Pruritus Product Development Milestones | 110 | 12 |
| Featured News &Press Releases | 110 | 1 |
| Jun 09, 2016: Cara Therapeutics to Present Preclinical Data at June Medical Meetings | 110 | 1 |
| Feb 18, 2016: Cara Therapeutics to Sponsor Symposium and Present Poster at the American Academy of Pain Medicine 32nd Annual Meeting | 110 | 1 |
| Oct 26, 2015: Cara Therapeutics to Present at 2nd Human Abuse Liability &Abuse-Deterrent Formulations Conference | 111 | 1 |
| Sep 09, 2015: Cara Therapeutics Initiates Phase 3 Program for I.V. CR845 in Acute Postoperative Pain | 112 | 1 |
| Jun 11, 2015: Tioga Pharmaceuticals Announces Initiation of Phase 2 Clinical Study of Asimadoline in Patients with Pruritus Associated with Atopic Dermatitis | 112 | 1 |
| May 12, 2015: Cara Therapeutics provides update on its Phase 3 Program for I.V. CR845 | 113 | 1 |
| Apr 15, 2015: Cara Therapeutics to Present at 3rd Conference on the Therapeutic Potential of Kappa Opioids | 114 | 1 |
| Mar 19, 2015: Creabilis CT327 Phase 2b Data Published in Acta Dermato-Venereologica, Strengthens Scientific Advisory Board | 114 | 1 |
| Mar 04, 2015: Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis | 115 | 2 |
| Jan 12, 2015: Creabilis Receives Positive Feedback on CT327 from US FDA, Providing Clear Path to Registration | 117 | 1 |
| Dec 17, 2014: Cara Therapeutics Reports Positive Top-Line Data From Phase 1b Trial of I.V. CR845 in Dialysis Patients | 117 | 1 |
| Dec 17, 2014: Velocity Pharmaceutical Development and Tigercat Pharma Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus | 118 | 1 |
| Aug 06, 2014: Cara Therapeutics Initiates Proof-of-Concept Phase II Trial of I.V. CR845 in Uremic Pruritus | 119 | 1 |
| Mar 21, 2014: Creabilis to Present CT327 Phase 2b Data at American Academy of Dermatology Annual Meeting | 119 | 1 |
| Jan 23, 2014: Start of Phase II study of neurokinin-1 receptor antagonist orvepitant for intense pruritus induced by epidermal growth factor receptor inhibitors | 120 | 2 |
| Appendix | 122 | 2 |
| Methodology | 122 | 1 |
| Coverage | 122 | 1 |
| Secondary Research | 122 | 1 |
| Primary Research | 122 | 1 |
| Expert Panel Validation | 122 | 1 |
| Contact Us | 122 | 1 |
| Disclaimer | 123 | 1 |
